Oxycodone for Postoperative Analgesia in Patients With Obstructive Sleep Apnea Undergoing Uvulopalatopharyngoplasty
10.11714/jsysu.med.YX20260099
- VernacularTitle:羟考酮用于阻塞性睡眠呼吸暂停患者的术后镇痛
- Author:
Mengjuan DENG
1
;
Jiali DENG
1
;
Shikun WEN
1
;
Liang XIAO
1
;
Yue PENG
1
Author Information
1. Department of Anesthesiology， The Eighth Affiliated Hospital， Sun Yat-sen University， Shenzhen 518033， China
- Publication Type:Journal Article
- Keywords:
oxycodone;
postoperative analgesia;
obstructive sleep apnea syndrome;
uvulopalatopharyngoplasty;
enhanced recovery after surgery
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2026;47(5):923-930
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the safety and efficacy of oxycodone versus sufentanil for postoperative analgesia in patients with moderate to severe obstructive sleep apnea （OSA） undergoing uvulopalatopharyngoplasty （UPPP）. MethodsWe enrolled 73 consecutive patients with moderate-to-severe OSA （confirmed by polysomnography） scheduled for elective UPPP under general anesthesia at our institution between August 2023 and August 2025. Patients were randomly assigned to receive oxycodone （n = 37） or sufentanil （n = 36） using a random number table . The sufentanil group received 1.5 μg per kilogram of body weight， and the oxycodone group received 0.9 mg per kilogram； both groups used patient-controlled intravenous analgesia （PCIA） pumps with a total volume of 100 mL. A 2 mL loading dose was administered 10 minutes before the end of surgery， followed by a background infusion of 2 mL per hour， 2 mL bolus doses on demand， an 8-minute lockout interval， and a maximum hourly volume of 10 mL. We assessed pain scores （Numerical Rating Scale） at rest and during swallowing， Ramsay sedation scores， morphine-equivalent opioid consumption， PCIA bolus demands， patient satisfaction， time to first oral intake， and adverse events （including respiratory depression， nausea， and vomiting） at 4， 12， 24， and 48 hours postoperatively. ResultsBaseline characteristics were well balanced between the two groups （all P＞0.05）. No significant between-group differences were observed in resting and swallowing NRS scores or Ramsay sedation scores at each postoperative time point， PCIA satisfaction， time to first oral intake， or adverse event incidence across all postoperative time points （all P＞0.05）. Morphine-equivalent opioid consumption was significantly lower in the oxycodone group at all time points， as were unsuccessful PCIA bolus demands at 24 and 48 hours postoperatively （both P＜0.05）. ConclusionsLow-dose oxycodone provided analgesic efficacy similar to that of sufentanil for PCIA after UPPP in patients with moderate-to-severe OSA， with no significant between-group differences in adverse events， time to first oral intake， or satisfaction .The oxycodone group had numerically lower adverse event rates and a shorter time to first oral intake， suggesting a favorable safety profile and potential benefits for reducing opioid-related events and facilitating earlier recovery in this patient population.
